McKesson stock broadens healthcare reach with Option Care deal
Published on 11/20/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDeal expands healthcare reach
- McKesson agreed to invest in a 49% minority stake in Option Care Health, subject to shareholder and regulatory approvals.
- The company completed its Precision Medicine Group acquisition in early November, adding clinical research and commercialization capabilities.
- Management expects the next fiscal third-quarter report in February 2027 to include Precision Medicine Group in the oncology and multispecialty segment.
On November 18, 2026, McKesson agreed to invest in a minority stake in Option Care Health, according to Trefis. The transaction would broaden the healthcare distributor's exposure beyond drug distribution into home and alternate-site infusion services.
New position in home infusion
McKesson agreed to invest about 1.4 billion US dollars for a 49% interest in Option Care Health. The transaction remains subject to approvals from Option Care Health shareholders and regulators, with completion expected in the first half of calendar 2027. Option Care Health is described as the largest independent provider of home and alternate-site infusion services in the United States.
Management linked the investment to a shift toward care delivered in lower-cost community settings, including locations closer to patients' homes. The transaction is not part of McKesson's current outlook, leaving its near-term earnings guidance focused on the existing business and the assets already included in its planning.
Precision Medicine adds oncology capabilities
The Option Care Health agreement came alongside McKesson's completed acquisition of Precision Medicine Group in early November. Precision Medicine Group provides clinical research and biopharma commercialization services in areas including oncology, rare and orphan diseases, and cell and gene therapies.
McKesson plans to report Precision Medicine Group within its oncology and multispecialty segment. That segment generated 48.4 billion US dollars in fiscal 2026 revenue, representing 12.0% of group revenue, while revenue increased 31.4% year over year. Management expects segment revenue to grow 20% to 24% in fiscal 2027.
Management expects Precision Medicine Group to add 0.10 to 0.20 US dollars to adjusted diluted earnings per share in fiscal 2027, with most of the contribution arriving in the fourth quarter. By the end of the acquisition's third year, management estimates an adjusted earnings contribution of 1.60 to 1.80 US dollars per share.
Next report will show integration
McKesson's fiscal third-quarter report is expected in February 2027. It will be the first quarterly report to include Precision Medicine Group in the oncology and multispecialty segment, giving investors a clearer view of how much of the segment's growth comes from the acquired business.
In the fiscal second quarter, the segment's operating profit rose 8% to 427 million US dollars. Management said profit increased 23% excluding 51 million US dollars of prior-year net gains within The U.S. Oncology Network. For fiscal 2027, the company expects oncology and multispecialty operating profit to grow 18% to 22%.
McKesson stock traded at 982.00 euros on Lang & Schwarz at 13:39 CET on Friday, November 20, 2026.
McKesson Corporation
- ISIN: US58155Q1031
- Lang & Schwarz quote: 982.00 euros at 13:39 CET on Friday, November 20, 2026
- Option Care Health investment: About 1.4 billion US dollars for 49%
- Expected closing: First half of calendar 2027, subject to approvals
The broader US market provides the relevant backdrop for McKesson stock through the S&P 500.
